Title : A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

Pub. Date : 2013 Sep

PMID : 23803225






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha2a (IFN; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). avoren interferon alpha 1 Homo sapiens